Process development services

Lonza Biologics Inc offers wide range of pharma products and services which includes custom powdered media . It belongs to upstream serum-free media and feed formulations services and products category. Features: non animal origin facility, relative humidity, consistent particl size distribution, batch cap...

Lonza Biologics Inc offers wide range of pharma products and services which includes nucleofector™ kit accessories. It belongs to bioresearch transfection services and produtcs category. . It includes nucleofector™ plus supplement, mouse t cell nucleofector™ medium, pmaxcloning™. It is ...

Lonza Biologics Inc offers wide range of pharma products and services which includes human mesenchymal stem cells & media. It belongs to primary and adult stem cells adult stem cells & media services & products category. It includes hmsc human mesenchymal stem cells, hmsc mesenchymal stem cell adipogenic d...

Lonza Biologics Inc offers wide range of pharma products and services which includes nucleofector™ technology. It belongs to bioresearch transfection services and produtcs category. It is a technology based on the momentary creation of small pores in cell membranes by applying an electrical pulse (ele...

Lonza Biologics Inc offers wide range of pharma products and services which includes pluripotent stem cell services. It belongs to pluripotent stem cells services category. It includes pharmaceutical companies looking to implement more biologically relevant cell models into their screening campaigns, trans...

Lonza Biologics Inc offers wide range of pharma products and services which includes primary cells media. It belongs to upstream serum-free media and feed formulations services and products category. Contact us for more information.

Lonza Biologics Inc offers wide range of pharma products and services which includes integrated technologiesLonza Biologics Inc offers wide range of pharma products and services which includes integrated technologies. It belongs to pharma & biotech, informatics moda™ , paperless qc micro solution ser...

With more than 40 years of experience in normal human cells and best-in-class cGMP compliance, Lonza Walkersville, Inc. is the industry leader in development, manufacturing and testing services for cell-based therapeutics. Our R&D organization has a wide range of expertise in technology and media deve...

Lonza Biologics Inc offers wide range of pharma products and services which includes media - fgm fibroblast growth media kits. It belongs to airway cells (normal & diseased) & media services and products category. It includes basal medium - contains no growth factors, cytokines, or supplements, singlequots...

Lonza Biologics Inc offers wide range of pharma products and services which includes melanocytes & medium. It belongs to primary and adult stem cells, human primary cells and media. It is pigment producing cells located in the epidermal layers of all mammalian skin. It is comprised of 2 main layers epiderm...

Lonza Biologics Inc offers wide range of pharma products and services which includes mesenchymal stem cell medium chemically defined. It belongs to cell culture products specialty media services and products category. It includes supports human mesenchymal stem cell growth (multi-potent adult stem cells), ...

Lonza Biologics Inc offers wide range of pharma products and services which includes moda-em™ paperless environmental monitoringLonza Biologics Inc offers wide range of pharma products and services which includes moda-em™ paperless environmental monitoring. It belongs to pharma & biotech, informatics ...

Follow along for live updates from the Content team as we bring you the latest from CPHI North America 2023 - from session talks, panel discussions, interviews, and more, there's a lot to discover with CPHI Online at the Pennsylvania Convention Center! 

Enabling a healthier world.

The offering will accelerate timelines for the development and manufacturing of molecules and disruptive technologies

Rapid and efficient development of drug candidates is increasingly important for pharmaceutical companies with accelerated timelines and funding constraints. However, many early drug candidates have poor oral absorption properties making it challenging to achieve target pharmacokinetic (PK) profiles. Without upfront knowledge of absorption risks and mitigation strategies, poor absorption can significantly impact preclinical and clinical study timelines and costs. Physiologically-based pharmacokinetic (PBPK) modeling software, such as the GastroPlus® platform from Simulations Plus, simulates dynamic physiological factors impacting oral performance. When coupled with in vitro measurements, PBPK modeling is effective in early development for 1) identifying absorption risks, 2) assessing the potential for solubility enhancing formulations such as salts, cocrystals, or amorphous solid dispersions to mitigate these risks, and 3) designing and optimizing preclinical and clinical studies with respect to dose, prandial state, or gastric pH modification to maximize the likelihood of achieving desired PK profiles. In this presentation, we will demonstrate how PBPK models combined with Lonza’s custom and off-the shelf in vitro tools and solubility enhancement expertise can be used to identify and mitigate absorption risks in early drug development, reducing the need for drug product reformulation or repeated preclinical or clinical studies. Key Learning Objectives: Learn how PBPK modeling can identify potential oral absorption risks and mitigation strategies (e.g. bioavailability enhancement) for early drug candidates. Learn how PBPK modeling coupled with in vitro testing can guide early selection of drug form and formulation to achieve clinical study goals. Gain insights into how key drug and formulation factors including solubility, permeability, and dissolution rate can impact absorption risks such as poor oral bioavailability, food-drug interactions, and pH-dependent DDI effects.

The expansion includes the installation of a pilot suite with a 50-L fermenter and automation upgrades to accelerate clinical and commercial projects

The companies will establish a Centre of Excellence focused on exosome manufacturing and characterization technologies